Federal contract award
140D0425P0179
RECOMBINANT HUMAN NT-3 PROTEIN, GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR, BRAIN-DERIVED NEUROTROPHIC FACTOR, LEUKEMIA INHIBITORY FACTOR, L-ASCORBIC ACID, JAGGED 1, CILIARY NEUROTROPHIC FACTOR, AND XAV 939.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of the Interior |
| Office | IBC ACQ SVCS DIRECTORATE (00004) |
| NAICS | 325414 — Biological Product (except Diagnostic) Manufacturing |
| PSC | 6505 — Drugs and Biologicals |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $70.4K |
| Current contract value | $70.4K |
| Potential contract value / ceiling | $70.4K |
| Start date | Sep 22, 2025 |
| Current end date | Dec 31, 2025 |
| Potential end date | Dec 31, 2025 |
| Latest award activity | Sep 18, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 1 of 1 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 18, 2025 | 0 | $70.4K | RECOMBINANT HUMAN NT-3 PROTEIN, GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR, BRAIN-DERIVED NEUROTROPHIC FACTOR, LEUKEMIA INHIBITORY FACTOR, L-ASCORBIC ACID, JAGGED 1, CILIARY NEUROTROPHIC FACTOR, AND XAV 939. |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.